10q10k10q10k.net
Viatris

ViatrisVTRSEarnings & Financial Report

Nasdaq · Health Care · Pharmaceuticals

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

NextFeb 27, 2026

VTRS Q3 2025 Key Financial Metrics

营收

$3.7B

毛利润

$1.4B

营业利润

$178.8M

净利润

N/A

毛利率

36.6%

营业利润率

4.8%

净利率

N/A

同比增长

0.3%

EPS

$-0.11

资金流向

Viatris Q3 2025 Financial Summary

Viatris reported revenue of $3.7B for Q3 2025, with a net profit of N/A (N/A margin). Cost of goods sold was $2.4B, operating expenses totaled $1.2B.

Key Financial Metrics

Total Revenue$3.7B
Net ProfitN/A
Gross Margin36.6%
Operating Margin4.8%
Report PeriodQ3 2025

Viatris Annual Revenue by Year

Viatris annual revenue history includes year-by-year totals (for example, 2024 revenue was $14.7B).

YearAnnual Revenue
2024$14.7B
2023$15.4B
2022$16.2B

利润表

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
营收$3.83B$3.65B$3.79B$3.74B$3.52B$3.24B$3.57B$3.75B
同比增长-1.1%-1.8%-3.2%-5.0%-8.1%-11.2%-5.7%0.3%

资产负债表

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
总资产$47.69B$47.34B$45.33B$44.75B$41.50B$38.47B$38.41B$37.92B
总负债$27.22B$27.33B$25.81B$24.96B$22.87B$22.82B$22.84B$22.70B
股东权益$20.47B$20.01B$19.52B$19.79B$18.64B$15.65B$15.57B$15.22B

现金流量表

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
经营性现金流$479.4M$614.6M$379.1M$826.5M$482.7M$535.5M$219.7M$744.9M